1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The myeloid cell biomarker EMR1 is ectopically expressed in colon cancer
(2021) In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 43(1). p.209-223
- Contribution to journal › Article
- 2017
-
Mark
Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model
(2017) In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 39(4).
- Contribution to journal › Article
- 2016
-
Mark
Vitronectin: a promising breast cancer serum biomarker for early diagnosis of breast cancer in patients.
(2016) In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
- Contribution to journal › Article
-
Mark
Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
(2016) In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
- Contribution to journal › Article
-
Mark
Association of DNA repair and xenobiotic pathway gene polymorphisms with genetic susceptibility to gastric cancer patients in West Bengal, India
- Contribution to journal › Article
- 2015
-
Mark
Radioimmunotherapy-a potential novel tool for pancreatic cancer therapy?
- Contribution to journal › Scientific review
-
Mark
miR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4
- Contribution to journal › Article
-
Mark
Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies : a pooled analysis of 25 randomized clinical trials
(2015) In Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 36(5). p.82-3471
- Contribution to journal › Article
- 2014
-
Mark
SOCS6 is a selective suppressor of receptor tyrosine kinase signaling
- Contribution to journal › Scientific review
- 2013
-
Mark
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
- Contribution to journal › Article
